Literature DB >> 12405251

Liver transplantation: the Italian experience.

S Fagiuoli1, V G Mirante, M Pompili, S Gianni, G Leandro, G L Rapaccini, A Gasbarrini, R Naccarato, L Pagliaro, M Rizzetto, G Gasbarrini.   

Abstract

BACKGROUND: Liver transplantation is the standard treatment for patients with end-stage liver disease no longer responsive to conventional medical treatment AIMS: To report the long-term experience of liver transplantation in Italy. PATIENTS AND METHODS: Data were obtained retrospectively by means of a multiple-item form collected from 15 Italian liver transplant centres. The filing centre was centralized.
RESULTS: A total of 3323 liver transplants were performed on 3026 patients, with a cumulative proportional survival of 72.4%. Three, 5 and 10 years' patient survival rates were 72.3%, 68.8% and 61.3%, respectively. The most common indication for liver transplantation were hepatitis B virus (+/- hepatitis D virus)- and hepatitis C virus-related cirrhosis (59.4%). Excellent survival rates were observed particularly in controversial indications, such as alcoholic cirrhosis, hepatitis B virus-related cirrhosis and hepatocellular carcinoma. Retransplantation was required in 8.9% of the cases. The overall prevalence of acute cellular rejection episodes was 43.5%. In our study population, primary non-function and disease recurrence were the most common causes of graft failure (28.7% and 25.4%, respectively). Infections and/or sepsis were the most common causes of death after transplantation (42%).
CONCLUSION: This study confirms that patients with controversial indications to liver transplantation such as alcoholic cirrhosis, HBV-related cirrhosis and hepatocellular carcinoma can achieve excellent survival when properly selected.

Entities:  

Mesh:

Year:  2002        PMID: 12405251     DOI: 10.1016/s1590-8658(02)80207-9

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  9 in total

1.  Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.

Authors:  Guy W Neff; Nyingi Kemmer; Tiffany E Kaiser; Victoria C Zacharias; Michele Alonzo; Mark Thomas; Joseph Buell
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

2.  Role of a CUF1/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans.

Authors:  Scott R Waterman; Moshe Hacham; Guowu Hu; Xudong Zhu; Yoon-Dong Park; Soowan Shin; John Panepinto; Tibor Valyi-Nagy; Craig Beam; Shahid Husain; Nina Singh; Peter R Williamson
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

3.  Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease.

Authors:  Stefano Targhetta; Federico Villamil; Paolo Inturri; Patrizia Pontisso; Stefano Fagiuoli; Umberto Cillo; Attilio Cecchetto; Simona Gianni; Remo Naccarato; Patrizia Burra
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

4.  Relationship between 13C-aminopyrine breath test and the MELD score and its long-term prognostic use in patients with cirrhosis.

Authors:  Edoardo G Giannini; Vincenzo Savarino
Journal:  Dig Dis Sci       Date:  2013-07-02       Impact factor: 3.199

5.  Clinical management of patients with recurrent viral hepatitis after liver transplantation.

Authors:  M Caremani; D Tacconi; P Giorni; L Lapini; S Corradini; R Giaccherini
Journal:  J Ultrasound       Date:  2007-04-16

6.  Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Authors:  Antonio Ascione; Massimo De Luca; Mario Melazzini; Simona Montilla; Maria Paola Trotta; Salvatore Petta; Massimo Puoti; Vincenzo Sangiovanni; Vincenzo Messina; Savino Bruno; Antonio Izzi; Erica Villa; Alessio Aghemo; Anna Linda Zignego; Alessandra Orlandini; Luca Fontanella; Antonio Gasbarrini; Marco Marzioni; Edoardo G Giannini; Antonio Craxì
Journal:  Infection       Date:  2018-05-28       Impact factor: 7.455

7.  Low molecular weight heparin in portal vein thrombosis of cirrhotic patients: only therapeutic purposes?

Authors:  Raffaele Licinio; Mariabeatrice Principi; Giuseppe Losurdo; Nicola Maurizio Castellaneta; Enzo Ierardi; Alfredo Di Leo
Journal:  ScientificWorldJournal       Date:  2014-12-29

8.  Antihepatitis C virus therapy in liver transplanted patients.

Authors:  Antonino Picciotto
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

9.  Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy.

Authors:  Francesco Saverio Mennini; Andrea Marcellusi; Massimo Andreoni; Antonio Gasbarrini; Salvatore Salomone; Antonio Craxì
Journal:  Clinicoecon Outcomes Res       Date:  2014-06-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.